In this review we aim to give an overview of these DC therapy trials which we categorized into four parts: DC therapy in NSCLC, DC/CIK cell therapy in NSCLC, AKT-DC therapy in NSCLC, and DC therapy in SCLC (Tables 1 and 2). This evidence concerns the gene AKT1 and non-small cell lung carcinoma.